INVA

Innoviva, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001080014
$22.33 -0.84% $1.6B
3 New Institutional Positions
Vol
Market Cap$1.6B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders9 funds
Inst. Value$340.7M
Inst. Activity3 buys / 0 sells
Reddit Sentiment67° Warm
SEC Reports3
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001080014·Prev Close $22.52

Recent Activity

May 22, 2026 short_volume
Short Volume: INVA — 82.1% short (0.6M / 0.7M)
Short: 589,297 | Exempt: 223,800 | TRF Vol: 717,911 | Short Ratio: 82.1% | Off-exchange volume (dark
May 20, 2026 Insider
Raifeld Pavel sold 1,130 shares
Chief Executive Officer @ $22.24 ($25.1K)
May 20, 2026 Insider
Zhen Marianne sold 1,127 shares
Chief Accounting Officer @ $22.24 ($25.1K)
May 20, 2026 Insider
Basso Stephen sold 559 shares
Chief Financial Officer @ $22.24 ($12.4K)
May 18, 2026 SEC
Innoviva reported the resignations of board members Derek Small and Mark DiPaolo to focus on their roles at Syndeio BioS
8-K — Impact 3/10
May 6, 2026 SEC
Innoviva reported Q1 2026 total revenue of $98.0M (+11% YoY, slightly below $101.6M consensus) and diluted EPS of $2.22,
8-K — Impact 5/10
Mar 27, 2026 SEC
Innoviva, Inc. filed an amended 10-K to include the audited consolidated financial statements of its majority-owned subs
10-K/A — Impact 3/10
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
839,865 shares ($16.8M)

Price Targets

$35.50 +57.5% upside Strong Buy
Current $22.54 Low $18.00 Median $39.00 High $46.00 4 analysts
$18.00 $46.00

Analyst Ratings

Strong Buy82% buy · 11 analysts
4Strong Buy
5Buy
1Hold
1Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 1, 2026 HC Wainwright & Co. REITERATE Buy → Buy
May 26, 2026 BTIG REITERATE Buy → Buy
May 7, 2026 BTIG MAINTAIN Buy → Buy
Feb 26, 2026 BTIG REITERATE Buy → Buy
Feb 17, 2026 BTIG INITIATE Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.50 $0.50 — $0.50 1
Next Q $0.46 $0.46 — $0.46 20% YoY 1
Current FY $1.91 $1.91 — $1.91 2% YoY 1
Next FY $2.21 ▼ -3.3% $2.21 — $2.21 16% YoY 1

Top Institutional Holders

FundValueMove
VANGUARD GROUP INC$158.3M
RENAISSANCE TECHNOLOGIES LLC$84.2M
BANK OF AMERICA CORP$30.4M
MORGAN STANLEY$28.4MADD
CHARLES SCHWAB INVESTMENT MANAGEMENT$20.4MNEW

Recent Insider Trades

DateInsiderTypeValue
May 20, 2026Raifeld PavelF$25.1K
May 20, 2026Zhen MarianneF$25.1K
May 20, 2026Basso StephenF$12.4K
May 18, 2026Linden JosephineA$0.00
May 18, 2026Linden JosephineA$0.00

Reddit Sentiment

67°
Warm
Bearish Neutral Bullish
2 mentions 2 bullish 0 bearish
9 institutional holders with $340.7M total value (17,045,966 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, BANK. Net buying activity: 3 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1VANGUARD GROUP INC7,917,103$158.3M46.4%
2RENAISSANCE TECHNOLOGIES LLC4,210,172$84.2M24.7%
3BANK OF AMERICA CORP /DE/1,519,203$30.4M8.9%
4MORGAN STANLEY1,418,739$28.4M8.3%ADD +50.6%
5CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,021,146$20.4M6.0%NEW
6TWO SIGMA INVESTMENTS, LP839,865$16.8M4.9%ADD +60.8%
7WELLS FARGO & COMPANY/MN70,238$1.4M0.4%ADD +71.4%
8FMR LLC29,032$580.3K0.2%DOUBLED +163.0%
9NORGES BANK20,468$409.2K0.1%NEW

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
TWO SIGMA INVESTMENTS, LPADD522,242839,865+60.8%$16.8M2025-Q4
WELLS FARGO & COMPANY/MNADD40,97070,238+71.4%$1.4M2025-Q4
NORGES BANKNEW20,468$409.2K2025-Q4
UBS Group AGDOUBLED251,869572,368+127.2%$10.4M2025-Q3
TWO SIGMA INVESTMENTS, LPADD331,886522,242+57.4%$9.5M2025-Q3
NORGES BANKEXIT68,8650-100.0%$0.002025-Q3
MORGAN STANLEYADD1,081,6581,629,205+50.6%$32.7M2025-Q2
TWO SIGMA INVESTMENTS, LPTRIM667,585331,886-50.3%$6.7M2025-Q2
UBS Group AGTRIM545,309251,869-53.8%$5.1M2025-Q2
NORGES BANKNEW68,865$1.4M2025-Q2
FMR LLCDOUBLED13,19634,703+163.0%$697.2K2025-Q2
CITADEL ADVISORS LLCDOUBLED328,416728,455+121.8%$13.2M2025-Q1
TWO SIGMA INVESTMENTS, LPDOUBLED262,739667,585+154.1%$12.1M2025-Q1
FMR LLCTRIM44,62313,196-70.4%$239.2K2025-Q1
NORGES BANKEXIT85,2820-100.0%$0.002025-Q1
UBS Group AGDOUBLED308,346676,469+119.4%$11.7M2024-Q4
CITADEL ADVISORS LLCTRIM502,355328,416-34.6%$5.7M2024-Q4
NORGES BANKTRIM210,00985,282-59.4%$1.5M2024-Q4
WELLS FARGO & COMPANY/MNADD26,38537,022+40.3%$642.3K2024-Q4
CHARLES SCHWAB INVESTMENT MANAGEMENT INCNEW732,296$14.1M2024-Q3
8 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 20, 2026Raifeld PavelChief Executive OfficerF1,130$22.24$25.1K
May 20, 2026Zhen MarianneChief Accounting OfficerF1,127$22.24$25.1K
May 20, 2026Basso StephenChief Financial OfficerF559$22.24$12.4K
May 18, 2026Linden JosephineDirectorA5,733$0.00$0.00
May 18, 2026Linden JosephineDirectorA9,166$0.00$0.00
May 15, 2026Raifeld PavelChief Executive OfficerA1,123$0.00$0.00
May 15, 2026Basso StephenChief Financial OfficerA1,123$0.00$0.00
May 4, 2026DiPaolo MarkDirectorA9,786$0.00$0.00
May 4, 2026Haimovitz JulesDirectorA9,786$0.00$0.00
May 4, 2026Small Derek ADirectorA10,000$0.00$0.00
May 4, 2026Basso StephenChief Financial OfficerA93,750$0.00$0.00
May 4, 2026Schlesinger Sarah J.DirectorA10,000$0.00$0.00
May 4, 2026Zhen MarianneChief Accounting OfficerA31,500$0.00$0.00
May 4, 2026Raifeld PavelChief Executive OfficerA312,500$0.00$0.00
May 4, 2026DiPaolo MarkDirectorA10,000$0.00$0.00
May 4, 2026Haimovitz JulesDirectorA10,000$0.00$0.00
May 4, 2026Zhen MarianneChief Accounting OfficerA12,766$0.00$0.00
May 4, 2026Raifeld PavelChief Executive OfficerA126,646$0.00$0.00
May 4, 2026Small Derek ADirectorA9,786$0.00$0.00
May 4, 2026Basso StephenChief Financial OfficerA37,994$0.00$0.00
May 4, 2026Schlesinger Sarah J.DirectorA9,786$0.00$0.00
Feb 20, 2026Raifeld PavelChief Executive OfficerF2,986$23.39$69.8K
Feb 20, 2026Basso StephenChief Financial OfficerF1,244$23.39$29.1K
Feb 20, 2026Zhen MarianneChief Accounting OfficerF2,460$23.39$57.5K

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 4 strong buy, 5 buy, 1 hold, 1 sell, 0 strong sell.

Analyst Price Targets

$35.50 mean target +57.5% upside Strong Buy (2.00)
$18.00 Low $46.00 High
MetricValue
Current Price$22.54
Target Low$18.00
Target Mean$35.50
Target Median$39.00
Target High$46.00
# Analysts4
RecommendationStrong Buy (2.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
$0.50 $0.50 $0.50 +0.0% 1↑ 1↓ $0.1B 10.7% 1
Next Q
2026-09-30
$0.46 $0.46 $0.46 19.6% +0.0% 0↑ 1↓ $0.1B 5.3% 1
Current FY
2026-12-31
$1.91 $1.91 $1.91 1.9% +0.0% 1↑ 1↓ $0.4B 7.1% 1
Next FY
2027-12-31
$2.21 $2.21 $2.21 15.7% -3.3% 0↑ 2↓ $0.5B 10.3% 1

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.500
7d ago$0.500
30d ago$0.500
60d ago$0.500
90d ago$0.535-0.035
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 1, 2026 HC Wainwright & Co. REITERATE Buy Buy
May 26, 2026 BTIG REITERATE Buy Buy
May 7, 2026 BTIG MAINTAIN Buy Buy
Feb 26, 2026 BTIG REITERATE Buy Buy
Feb 17, 2026 BTIG INITIATE Buy
Dec 16, 2025 HC Wainwright & Co. MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264511082%
May 1, 20264511082%
Apr 1, 20264511082%
Mar 1, 20264511082%
Feb 1, 20263511080%
Jan 1, 20263511080%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

67°
Warm
Bearish Neutral Bullish
2 mentions 2 bullish 0 bearish 2 time periods

Reddit Sentiment History

DateMentionsSentimentBullishBearishThreads
Apr 22, 2026160° Warm101
Apr 22, 2026160° Warm101

Recent Reddit Threads

r/options Bullish 1mo ago
Plenty of good opportunities, but no volume / open interest
▲ 1 💬 0 ⚡ 0.5
May 22, 2026
short_volume
Short Volume: INVA — 82.1% short (0.6M / 0.7M)
Short: 589,297 | Exempt: 223,800 | TRF Vol: 717,911 | Short Ratio: 82.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
INVA Q1 2026 Earnings Scheduled — 2026-05-13
May 5, 2026
earnings_calendar
INVA Q1 2026 Earnings Scheduled — 2026-05-05
Mar 4, 2026
earnings_calendar
INVA Q4 2025 Earnings After Market Close — 2026-03-04
Dec 15, 2025
fda_pdufa
PDUFA: INVA — zoliflodacin in uncomplicated gonorrhea in adults and pediatric patients 12 years and older — 2025-12-15
FDA target action date 2025-12-15 for INVA (Innoviva, Inc.). Drug: zoliflodacin. Indication: uncomplicated gonorrhea in adults and pediatric patients